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OBJECTIVE — Eliminating health disparities is a national priority, but progress has been
difﬁcult because of racial/ethnic differences in insurance coverage and access to health care. We
investigatedwhetherthereweredifferencesindiabetescareintheVeteransAdministration(VA),
where health care access should be relatively uniform.
RESEARCH DESIGN AND METHODS — A1C and plasma glucose were compared
before/after diagnosis of diabetes.
RESULTS — Data were available for 1,456 black and 2,624 white veterans who met criteria
forconsistentprimarycare.Over4–5yearsbeforeandafterdiagnosis,blackshadsimilarglucose
and 0.2% higher A1C levels than whites, and A1C differences could be attributed to glucose-
independent associations between race and A1C. Blacks and whites also had comparable inter-
vals between diagnostic-level hyperglycemia and diagnosis and between diagnosis and drug
initiation. However, A1C was higher in blacks at the time of diagnosis (7.8 vs. 7.1%) and at
initiation of pharmacotherapy (8.5 vs. 7.8%) (both P  0.001). Differences in A1C at diagnosis
and drug initiation were too large to be explained by differences in age, sex, BMI, and glucose-
independent associations between race and A1C.
CONCLUSIONS — In the VA, glucose levels are generally comparable in blacks and whites
except at the times of diagnosis and initiation of pharmacotherapy, when glucose levels are
higher in blacks. While understanding the basis for such residual disparities may be important
to improve the health of racial/ethnic minorities in the U.S., a health care system with structure
andorganizationsimilartothatintheVAmayalsocontributeimportantlytorelievingdisparities
in health.
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R
acial/ethnic minorities in the U.S.
suffer from disparities in diabetes-
related health. Minority groups
have a high prevalence of type 2 diabetes
(1), and the public health impact of the
increased prevalence of diabetes in mi-
norities is exacerbated by related morbid-
ity and mortality that are higher than in
whites (2). During the 1980s, diabetes-
related mortality for white men and
women decreased 1.6 and 4.5%, respec-
tively, yet mortality increased among
blacks 11 and 5.5%, respectively. Among
blacks with diabetes, hypertension, pe-
ripheralvasculardisease,andretinopathy
areallmorecommonthaninwhites.Sim-
ilarly, end-stage renal disease (3), lower-
extremity amputations related to diabetes
(4), and rates of hospitalization and dis-
ability due to diabetes for blacks are
nearly double those for whites; increased
diabetes morbidity remains after adjust-
ment for prevalence of hypertension (3).
Such increased morbidity appears to
be due at least in some part to poor met-
abolic control (5). Blacks in the National
Health and Nutrition Examination Sur-
veys (NHANES) 1988–1994 and 1999–
2002 had the highest prevalence of A1C
8% and highest average A1C compared
withotherethnicgroups(6),andasimilar
disparity was found in a Kaiser Perma-
nente population (7). Such disparities are
thought to reﬂect differences in socioeco-
nomic status (8) and insurance coverage
and related access to care (9). If such fac-
tors are the dominant basis for disparities
in health, then disparities should not be
present in settings where access to care is
relativelyuniform.Wetestedthishypoth-
esis by comparing glucose and A1C levels
inveteransreceivingconsistentfollow-up
care at medical centers in the southeast-
ern U.S.
RESEARCH DESIGN AND
METHODS— This study was ap-
proved by the Emory University Institu-
tional Review Board. The sample
population was a retrospective cohort of
patients identiﬁed in the Corporate Data
Warehouse for the Veterans Integrated
Service Network (VISN) 7 (Veterans Ad-
ministration [VA] medical centers in
South Carolina, Georgia, and Alabama).
We selected patients who had 1) diabetes
diagnosed on 1 October 2002 or later, 2)
consistent primary care (three or more
visits over 2 years before the date of di-
agnosis, and four or more visits over 3
years after the diagnosis, including the
“diagnostic” visit as one of the visits), 3)
race information available, and 4) A1C
and random plasma glucose values avail-
able within 3 months before and 6 weeks
after the index date; the relatively modest
requirement for consistent primary care
(essentiallyonevisitayear)isnecessaryto
ensure that providers have had some op-
portunity to interact with the patients. In
this VISN, 269,434 veterans had a pri-
mary care visit in 2008, and 44,806 had




1Division of Endocrinology and Metabolism, Emory University School of Medicine, Atlanta,
Georgia; the
2Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory
University, Atlanta, Georgia; the
3Division of Cardiology, Emory University School of Medicine, Atlanta,
Georgia; the




School of Public Health, Emory University, Atlanta, Georgia; the
7Division of Endocrinology and Metab-
olism, Department of Medicine, University of Western Ontario, London, Ontario, Canada; and the
8Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta,
Georgia.
Corresponding author: Lawrence S. Phillips, medlsp@emory.edu.
Received 19 August 2009 and accepted 20 January 2010. Published ahead of print at http://care.
diabetesjournals.org on 26 January 2010. DOI: 10.2337/dc09-1556.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
958 DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 care.diabetesjournals.orgtwo or more outpatient glucose measure-
ments each year; 5,436 met our diabetes
selection criteria, and 4,080 of these had
race information available. A smaller
number also had A1C and random
plasma glucose values available at differ-
ent time points (see text and the ﬁgure
and table legends).
The date of hyperglycemia in the dia-
betes range was assigned according to the
date of having any value twice or any two
of outpatient random plasma glucose val-
ues 126 mg/dl before 10:00 A.M., ran-
domplasmaglucose200mg/dlatalater
time, or A1C 6.5% (random plasma
glucose 125 mg/dl or A1C 6.5% con-
fers a high likelihood of having diabetes
[10,11],andVAhealthcareprovidersfre-
quently check A1C levels in patients not
known to have diabetes). The date of di-
agnosis was assigned according to initial
use of the diabetes ICD-9 code 250.xx in
primary care, use of the code twice in any
setting, or prescription of a diabetes drug
(whichever came ﬁrst)—criteria estab-
lishing the disease (12). The use of med-
ications was assessed during the period
between12and24monthsaftertheindex
date. Medications were categorized as
metformin, sulfonylureas, thiazo-
lidinediones, insulin, and “other;” pa-
tients could be using more than one drug
at a time.
Glucose and A1C values were as-
sessed from 3 months before to 6 weeks
after the dates of 1) diabetes-range hyper-
glycemia, 2) diagnosis, and 3) initial pre-
scription of a diabetes drug. Values were
also averaged over each of 1–4 years be-
fore diagnosis and 1–5 years after diagno-
sis. We included all A1C measurements,
but to minimize potential confounding
due to the stress of acute illnesses, we ex-
cluded glucose values obtained during
hospitalizations. Glucose measurements
were relatively common before diagnosis
(a minimum of 371 measurements in
blacks at year 4), whereas A1C mea-
surements were less frequent (57 mea-
surementsinblacksatthattime),butA1C
measurements were more common after
theindexdate(aminimumof201glucose
and 333 A1C measurements in blacks at
year 5).
Glucose and A1C were measured in
VA clinical chemistry laboratories. Glu-
cose was assessed with U.S. Food and
Drug Administration–approved plat-
forms such as the Beckman DXC or LX20
(Beckman Coulter, Fullerton, CA) or
Roche P or COBAS (Roche Diagnostics,
Indianapolis, IN), and A1C with National
Glycohemoglobin Standardization Pro-
gram–approved methods, mainly high-
performanceliquidchromatographysuch
astheTosohG7(TosohBioscience,South
San Francisco, CA), but also immunolog-
ical methods (from both Beckman
Coulter and Roche Diagnostics).
For descriptive statistics, continuous
variables were analyzed by t tests and cat-
egoricalvariablesby
2orMann-Whitney
U tests. Multiple linear regression models
were used to assess the relationship be-
tween A1C values and race, adjusting for
potential confounders including glucose.
All analyses used SAS version 9.2 (SAS
Institute, Cary, NC).
RESULTS— The 4,080 study patients
were younger and included more women
than the 1,356 patients who lacked race
information: age 62 vs. 66 years (P 
0.0001), 2.8 vs. 1.2% female (P 
0.0001), and BMI 30.1 vs. 30.1 kg/m
2
(P0.97),respectively.Amongthestudy
patients (Table 1), blacks were younger
than whites (58 vs. 65 years) and more
likely to be female (4.9 vs. 1.6%) (both
P  0.001), but had comparable BMI
(30.3 vs. 30.0 kg/m
2, P  NS). The aver-
age date of initial diabetes diagnosis was
16October2003forblacksversus27Oc-
tober 2003 for whites (P  NS), and the
period between initial diabetes-level hy-
perglycemia and diagnosis was compara-
ble in blacks versus whites (479 vs. 504
days,PNS);medicationswereinitiated
slightly earlier after the date of diagnosis
in blacks (290 vs. 328 days, P  0.04).
Between12and24monthsaftertheindex
date, medications were used slightly but
signiﬁcantly more often in blacks (91 vs.
88%, P  0.022), including metformin
(34 vs. 29%, P  0.002), sulfonylureas
(29 vs. 26%, P  0.048), and insulin (5.4
vs. 3.6%, P  0.005); there were no sig-
niﬁcant differences in use of thiazo-
lidinediones(7.0vs.7.3%)orotherdrugs
(0.3 vs. 0.7%).
Figure 1 shows A1C and random
plasma glucose levels for blacks and
whites at each of years 1–4 before diag-
nosis, at diagnosis, and years 1–5 after
diagnosis. Both at years 1–4 before and
years 1–5 after the date of diagnosis, ran-
dom plasma glucose levels in blacks were
generally slightly but not signiﬁcantly
lower than values in whites. Including
both blacks and whites, A1C averaged
6.4% at years 1–4 before diagnosis and
6.9% at years 1–5 after diagnosis. Despite
the similarity in random glucose levels, at
both years 1–4 before and years 1–5 after
the date of diagnosis, A1C levels in blacks
were slightly but signiﬁcantly higher than
values in whites (average difference
0.11% before diagnosis and 0.24% after
diagnosis, all P  0.005 for blacks versus
whitesexceptforyears3and1before
diagnosis). After adjusting for age, BMI,
and medical center, blacks had A1C val-
uesthatwere0.20higherthaninwhites2
years before diagnosis and 0.22 higher 2
years after diagnosis. These small differ-
ences were generally within the range at-
tributable to the glucose-independent
association between race and A1C (see
below).
In contrast, blacks had signiﬁcantly
higher levels of both plasma glucose and
A1C at both the date of diagnosis (154 vs.
148 mg/dl and 7.77 vs. 7.11%) and when
a glucose-lowering medication was ﬁrst
prescribed (176 vs. 169 mg/dl and 8.53
vs. 7.84%) (all P  0.05) (Table 2). The
differences in A1C at the times of diagno-
sis (0.66%) and ﬁrst medication prescrip-
Table 1—Patient characteristics at time of diagnosis of diabetes
Black White P
n 1,456 2,624
Age (years) 57.8 (57.3–58.3) 64.9 (64.5–65.3) 0.001
Sex (% female) 4.9 (3.8–6.0) 1.6 (1.1–2.1) 0.001
BMI (kg/m
2) 30.3 (30.0–30.6) 30.0 (29.8–30.2) 0.18
Date of diagnosis (month/day/year) 10/16/03 10/27/03 0.86
Days hyperglycemia to diagnosis
Mean (95% CI) 479 (454–504) 504 (485–523) 0.22
Median (interquartile range) 333 (31–770) 356 (62–820) 0.12
Days diagnosis to initial drug Rx
Mean (95% CI) 290 (265–315) 328 (309–347) 0.04
Median (interquartile range) 3 (0–427) 5 (0–537) 0.03
Data are percent and are either means (95% CI), with differences tested by t test, or median (interquartile
range), with differences tested by Mann-Whitney U test.
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attributable to the glucose-independent
association between race and A1C. As
shown by the multivariate analyses in Ta-
ble 3, at both of these times, A1C levels
were not inﬂuenced by the date of mea-
surement and were slightly higher with
greater BMI and either slightly lower or
not inﬂuenced by greater age. A1C was
more strongly affected by the level of ran-
dom plasma glucose and by the time of
dayglucosewasmeasured(likelybecause
of the Staub-Traugott effect [13], glucose
toleranceisbetteraftermeals[andlaterin
the day], so the same glucose value ob-
tained later in the day reﬂects a higher
A1C level). After adjusting for such con-
founders, the glucose-independent asso-
ciation between black race and A1C was
0.24% (units) at the time of initial diabe-
tes-levelhyperglycemia,0.38%atdiagno-
sis,and0.40%attheﬁrstprescriptionofa
diabetes drug (all P  0.001). Although
sex was not included as a covariate be-
causeofsmallnumbers,theﬁndingswere
changed only in the second decimal in
analyses which included only men (not
shown).
The differences in A1C between
blacks and whites at diagnosis and initial
pharmacotherapy were not associated
with differences in numbers of visits or




visits, 5.2 vs. 5.1 random plasma glucose
measurements, and 2.2 vs. 2.3 A1C mea-
surements (all P  NS). Between diagno-
sis and the ﬁrst prescription of a
diabetes drug, blacks and whites aver-
aged5.7vs.6.0outpatientvisits,3.8vs.
3.5 random plasma glucose measure-
ments, and 3.2 vs. 3.3 A1C measure-
ments (all P  NS).
CONCLUSIONS — Ourresultsdem-
onstrate that race is not a signiﬁcant de-
terminant of good metabolic control of
diabetesinveteranswithadequatefollow-
up. Among patients receiving consistent
primary care in VA medical centers in
South Carolina, Georgia, and Alabama,
blacks and whites diagnosed with diabe-
tes generally had fairly good metabolic
control, with A1C levels at 6.4% at
years 1–4 before and 6.9% at years 1–5
after diagnosis. At these times, blacks had
similar glucose levels and 0.2% higher
A1C levels than whites, and these differ-
ences in A1C were in the range attribut-
able to the glucose-independent
association between race and A1C. How-
ever, blacks had higher A1C and glucose
levelsthanwhiteswhenthediagnosiswas
made and when the ﬁrst diabetes drug
was prescribed. Moreover, the disparities
in A1C at these times (0.6–0.7%) were
Figure1—LevelsofA1C(A)andrandomplasmaglucose(B)inblackandwhiteveteransbeforeand
after the diagnosis of diabetes. Years before and after the date of diagnosis are shown and measures
averagedforeachpatientwithin6monthsbeforeand6monthsafterthedateofdiagnosisandeachyear
before and after the date of diagnosis. Data are means  SEM. Numbers of black and white veterans,
respectively,contributingtodatapointswereasfollows:year4,126and244;year3,217and434;
year 2, 389 and 742; year 1, 570 and 1,047; year 0, 1,258 and 2,166; year 1, 1,218 and 2,183;
year 2, 1,199 and 2,198; year 3, 1,240 and 2,207; year 4, 1,063 and 1,846; year 5, 571 and 953.
Table2—RandomplasmaglucoseandA1Cinblackandwhiteveteranswithin3monthsbefore




At date of diabetes diagnosis (mg/dl) 154  79 148  61 0.035
n 1,054 1,924
At start of diabetes medication (mg/dl) 176  88 169  69 0.041
n 730 1,321
A1C
At date of diabetes diagnosis (%) 7.77  2.37 7.11  1.60 0.001
n 993 1,635
At start of diabetes medication (%) 8.53  2.46 7.84  1.74 0.001
n 798 1,321
Data are numbers of subjects with measurements available and are means  SD. More patients had either
glucose or A1C available than had both glucose and A1C available.
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independent association between race
and A1C and were not associated with
having fewer visits or glucose or A1C
measurements.
The pattern of a gradual rise in glu-
coseandA1Clevelsoveryears1–4before
diagnosis,followedbyamorerapidrisein
glucose and A1C during the year prior to
diagnosis, is consistent with previous re-
ports (14,15); we also found a further in-
crease in glycemia before initiation of
pharmacotherapy. The factors contribut-
ing to the rapid rise are not known but
might include a “vicious cycle” of effects
ofhyperglycemia-inducedincreasesinin-
ﬂammation and oxidative stress on sus-
ceptible 	-cells. Our ﬁndings of a
glucose-independentassociationbetween
raceandA1Carealsoconsistentwithpre-
vious reports (16); the basis for glucose-
independent higher A1C in blacks is also
not known.
Despite patient characteristics that
predispose to poorer health, direct com-
parisons have generally shown better di-
abetes care in VA settings than non-VA
settings.Veteranstendtobenonwhite,be
unemployed, and have lower income,
lower health status, and higher illness
burden than nonveterans (17), factors
that increase the likelihood of poor-
quality health care (18). However, pa-
tients managed in VA settings receive
better diabetes-related processes of care
(19) and exhibit lower A1C levels (20).
Good VA care has been attributed to a
combination of structural organization,
use of electronic medical records and
monitored “quality indicators,” and em-
phasis on evidence-based practice guide-
lines (21). But even within the VA, blacks
are somewhat less likely than whites to
have A1C 7% (22).
A meta-analysis in 2006 found A1C
levels to average 0.65% higher in blacks
than in whites (5). In the NHANES na-
tionallyrepresentativesamplesoftheU.S.
population, A1C levels were 8.21% in
blackswithdiagnoseddiabetescompared
with 7.60% in whites in 1988–1994 and
8.02 vs. 7.30% in 1999–2002 (23), im-
proving in both groups, but persistently
worse in blacks. In NHANES 1999–
2002, the likelihood of A1C 7% in
blacks versus whites was unaffected by
adjustment for age, sex, level of educa-
tion, poverty level, and insurance cover-
age (6), but such adjustments may not
fully account for the contributions of so-
cio-ecologic factors. In the Translating
Research Into Action for Diabetes
(TRIAD) Study of an insured population,
where A1C measurement was less fre-
quentandA1Clevelswere0.2%higherin
blacks than in whites (24), cost-related
underuse of medications was also signiﬁ-
cantly higher in blacks than in whites (8),
due in part to lower income and higher
out-of-pocket drug costs.
Incontrast,ouranalysisshowsthatin
the VA setting, glucose levels are compa-
rable or lower in blacks than in whites,
and A1C levels are generally only mod-
estly higher in blacks than in whites (and
within the range attributable to the glu-
cose-independent association between
race and A1C). These ﬁndings are consis-
tent with our previous observation in a
municipal hospital population that racial
disparities in glycemic control are largely
abolished by use of a uniform treatment
algorithm, under which rates of provider
intensiﬁcation of therapy and patient
medication adherence were comparable
(25). Presumably, the VA “system” of ac-
cess to care, low cost for medications, use
of quality indicators, and guideline-based
management (above) helps to minimize
potential disparities. However, these ap-
proaches may apply less well to the more
dynamic processes of making the diagno-
sis and initiating pharmacotherapy; fur-
ther studies will be required to explain
why A1C is higher in blacks than in
whites in the 1- to 2-year period around
the times of diagnosis and initiation of di-
abetes medications.
The strengths of our study include a
large number of patients, and availability
oflongitudinalinformationfrommultiple
medical centers across three states, per-
mitting us to compare groups of patients
who had consistent primary care fol-
low-up before and after the diagnosis of
diabetes was made. Limitations include
the lack of a national sample, patients
who were largely male, lack of informa-
tion on race in a substantial number of
patients, and non-uniform measurement
of A1C and glucose levels; the last reﬂects
real-worldasopposedtoclinicaltrialcon-
ditions. Our ﬁndings apply to patients
who have consistent follow-up care simi-
lar to patients in the present study;
whethertheconsistencyoffollow-upcare
differs according to race is beyond the
scope of our analysis. While further stud-
ies would be required to determine
whether the ﬁndings would be similar in
patients who had less than one primary
care visit a year, it could also be argued
Table 3—Multivariate regression analysis of factors inﬂuencing A1C
Coefﬁcient SEM P
At time of diabetes-level hyperglycemia
(n  1,335)
Random plasma glucose (mg/dl) 0.018 0.0005 0.0001
Time of day of random glucose (hours
since midnight) 0.102 0.016 0.0001
Actual date (days since 10/1/2002) 0.00002 0.00013 0.8685
Age (years) 0.0049 0.0033 0.1381
BMI (kg/m
2) 0.00297 0.00658 0.6516
Black race 0.245 0.069 0.0004
At time of diagnosis of diabetes (n  2,144)
Random plasma glucose 0.0184 0.0004 0.0001
Time of day of random glucose 0.032 0.013 0.0166
Actual date 0.00001 0.00012 0.9273
Age 0.0077 0.0031 0.0113
BMI 0.01780 0.00597 0.0029
Black race 0.383 0.065 0.0001
At time of initial prescription of diabetes
medication (n  1,686)
Random plasma glucose 0.0166 0.0005 0.0001
Time of day of random glucose 0.027 0.018 0.1244
Actual date 0.00006 0.00008 0.4150
Age 0.0071 0.0040 0.0801
BMI 0.01639 0.00752 0.0295
Black race 0.405 0.082 0.0001
Adjustment also included medical center (not shown). A1C is the dependent variable in the model; white
race was the racial reference value. Positive estimate values show the extent to which unit changes in the
factor contribute to higher A1C values, and negative estimate values show the converse.
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visit a year would not constitute a mean-
ingful measure of primary care practice in
any health care setting. It should also be
recognized that care in the VA is not nec-
essarily “free,” since some categories of
eligibility require a copayment for
pharmaceuticals or services received.
However,suchrequirementsarestratiﬁed
according to service connection, income,
and insurance coverage, which should
minimize the impact of differences in ﬁ-
nancial status (8).
In conclusion, we found that differ-
ences in A1C between black and white
veterans were generally small and within
the range associated with race, per se,
without a difference in underlying glu-
cose levels. However, even in the VA,
blacks had higher A1C levels than whites
when the diagnosis was made and when
drug treatment was initiated, and at these
times,thedifferencesinA1Creﬂectedun-
derlying differences in glycemia as well.
While understanding the basis for such
residual disparities may be important to
improving the health of racial/ethnic mi-
norities in the U.S., our overall ﬁnding
may indicate that racial disparities in
healthcanbeexpectedtobeminimizedin
health care systems that provide features
of structure and organization comparable
to those of the VA.
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